BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
6.13
-0.27 (-4.22%)
Feb 13, 2026, 4:00 PM EST - Market closed
BiomX Employees
As of December 31, 2024, BiomX had 57 total employees, including 52 full-time and 5 part-time employees. The number of employees decreased by 14 or -19.72% compared to the previous year.
Employees
57
Change (1Y)
-14
Growth (1Y)
-19.72%
Revenue / Employee
n/a
Profits / Employee
-$655,702
Market Cap
9.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 57 | -14 | -19.72% | 52 | 5 |
| Dec 31, 2023 | 71 | 6 | 9.23% | 58 | 13 |
| Dec 31, 2022 | 65 | -54 | -45.38% | 54 | 11 |
| Dec 31, 2021 | 119 | 13 | 12.26% | 103 | 16 |
| Dec 31, 2020 | 106 | 20 | 23.26% | 95 | 11 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| CytoMed Therapeutics | 43 |
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| CalciMedica | 15 |
| XTL Biopharmaceuticals | 10 |
| TransCode Therapeutics | 7 |
| Ernexa Therapeutics | 6 |
PHGE News
- 18 days ago - BiomX Issues Statement Regarding Recent Common Stock Trading Activity - GlobeNewsWire
- 6 weeks ago - BiomX Announces $3.0 Million Private Placement - GlobeNewsWire
- 2 months ago - BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Benzinga
- 2 months ago - BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis - GlobeNewsWire
- 3 months ago - BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates - GlobeNewsWire
- 4 months ago - BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways - GlobeNewsWire
- 6 months ago - BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - GlobeNewsWire